Copyright
©2009 The WJG Press and Baishideng.
World J Gastroenterol. Jun 14, 2009; 15(22): 2782-2786
Published online Jun 14, 2009. doi: 10.3748/wjg.15.2782
Published online Jun 14, 2009. doi: 10.3748/wjg.15.2782
Table 1 Patient characteristics before beginning the study (mean ± SE)
| Total (n = 32) | |
| Mean age (range) | 65.8 ± 2.6 (43-80) |
| Gender (male) | 18 (56) |
| Liver cirrhosis (%) | 7 (22) |
| Controlled hepatocellular carcinoma (%) | 4 (12) |
| Glycyrrhizin administration (%) | 6 (19) |
| AST (IU/L) | 66.5 ± 4.1 |
| ALT (IU/L) | 57.1 ± 3.4 |
| GGT (IU/L) | 44.2 ± 2.1 |
| Total bilirubin (mg/dL) | 0.76 ± 0.5 |
| Serum albumin (g/dL) | 4.0 ± 0.1 |
| Platelet count (× 1000/&mgr;L) | 14.5 ± 1.0 |
| HCVRNA (KIU/mL) | 1309 ± 469 |
| HCV genotype (1b/non 1b/not decided) | 24/6/2 |
- Citation: Sato S, Miyake T, Tobita H, Oshima N, Ishine J, Hanaoka T, Amano Y, Kinoshita Y. A dose-up of ursodeoxycholic acid decreases transaminases in hepatitis C patients. World J Gastroenterol 2009; 15(22): 2782-2786
- URL: https://www.wjgnet.com/1007-9327/full/v15/i22/2782.htm
- DOI: https://dx.doi.org/10.3748/wjg.15.2782